Other FDA Approved

Copper Cu-64 Dotatate

A positron-emitting somatostatin analog in which the octapeptide DOTA-Tyr3-octreotate carries copper-64 to somatostatin receptor-positive cells, FDA approved since September 3, 2020 as the PET imaging agent Detectnet for localizing neuroendocrine tumors in adults.

RadiopharmaceuticalSomatostatin AnalogNeuroendocrinePET ImagingFDA Approved

Also referenced as: Detectnet, 64Cu-DOTATATE, Cu-64 DOTATATE, 64Cu-DOTA-TATE, Copper (64Cu) oxodotreotide, NETMedix

Also appears in: Hormone

Public product evidence No certificate records are bound to a tracked Copper Cu-64 Dotatate product page A record counts here only when a vendor publishes a certificate against one of its own tracked Copper Cu-64 Dotatate product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
FDA Approved

This compound maps to at least one regulated medical product or label context in the United States.

Research area
Other research areas

Primary research area: Other. Also surfaces under Hormone for browsing and discovery.

Body systems
Gut · Hormones

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
6

Detectnet, 64Cu-DOTATATE, Cu-64 DOTATATE, 64Cu-DOTA-TATE, Copper (64Cu) oxodotreotide, NETMedix

Signal depth
Medium

FDA label signal · 16 trials · 47 PubMed results

Established

Copper Cu-64 Dotatate is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Copper Cu-64 Dotatate has 4 name-matched clinical trials (highest phase: Phase 2) and 47 PubMed-indexed publications and holds an FDA drug label. Human trials are registered but none have posted results yet. Note: 1 retracted publication in the literature.

⚠ 1 retracted publication
Human data
Approved drug
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Multiple trials
Literature
High-impact

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Copper Cu-64 Dotatate?

Copper Cu-64 dotatate is a radiolabeled somatostatin analog: the cyclic octapeptide octreotate (D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr with a 2-7 disulfide bridge, which is octreotide with a C-terminal threonine in place of threoninol and a tyrosine at position 3) linked through the chelator DOTA to the positron emitter copper-64. The US label gives the molecular weight of the labeled conjugate as 1,497.2 Da. The peptide-chelator portion is identical to the vector in gallium Ga-68 dotatate (NETSPOT) and in the therapeutic lutetium Lu-177 dotatate (Lutathera); only the metal differs. The international nonproprietary name for the conjugate is oxodotreotide, so the drug is also written copper (64Cu) oxodotreotide.

Marketed as Detectnet by Curium under an application originally submitted by RadioMedix, it was approved by the FDA on September 3, 2020 for use with positron emission tomography (PET) to localize somatostatin receptor-positive neuroendocrine tumors (NETs) in adults. The practical case for a copper version of an already-approved gallium tracer is logistical: copper-64 has a half-life of 12.7 hours against 68 minutes for gallium-68, so the finished product can be made centrally and shipped as a ready-to-inject vial rather than labeled on site from a generator kit. It is a diagnostic, not a treatment, is handled only by licensed nuclear medicine facilities, and has no research-market presence; the unlabeled DOTA-octreotate precursor is a specialty radiochemistry reagent.

How it works

  • Receptor binding. Well-differentiated NETs overexpress somatostatin receptors, especially subtype 2 (SSTR2). In receptor-subtype assays, DOTA-Tyr3-octreotate bound SSTR2 with low-nanomolar affinity (IC50 1.6 nM for the yttrium-chelated form and 0.2 nM for the gallium-chelated form), and the study showed that the chelated metal itself changes the subtype affinity profile (Reubi et al., European Journal of Nuclear Medicine, 2000, 27(3):273-282). The label states that copper Cu 64 dotatate binds with highest affinity to SSTR2, that uptake intensity indicates receptor density rather than tumor size, and that the highest normal-organ activity 1 to 3 hours after injection is in adrenal glands, kidney, pituitary, spleen and liver.
  • Copper-64 physics. Copper-64 decays with a half-life of 12.7 hours by three routes: 17.6% positron emission to nickel-64, 38.5% beta-minus decay to zinc-64 and 43.8% electron capture to nickel-64. Only the positron branch yields the paired 511 keV photons a PET scanner detects, so the positron yield is far lower than gallium-68’s, but the low maximum positron energy (0.653 MeV) sharpens resolution and the long half-life allows a wide imaging window; the first-in-humans study calculated an effective dose of 6.3 mSv for 200 MBq, with the liver the highest-dose organ at 0.16 mGy/MBq (Pfeifer et al., Journal of Nuclear Medicine, 2012, 53(8):1207-1215). The label gives about 4.7 mSv for the approved 148 MBq activity.
  • A stable, extended imaging window. In 35 patients scanned at both 1 and 3 hours after injection of 200 MBq, 822 lesions were concordant and only 5 discordant, with liver tumor-to-normal ratios of 12.6 at 1 hour and 11.0 at 3 hours, so imaging can take place anywhere from 1 to 3 hours without a significant difference in lesions detected (Loft et al., Journal of Nuclear Medicine, 2021, 62(1):73-80).
  • Receptor competition and off-target uptake. Unlabeled octreotide and lanreotide compete for SSTR2 and can reduce tracer uptake. SSTR2 is also expressed on macrophages, and 64Cu-DOTATATE uptake in large arteries correlated with Framingham risk score in 60 NET patients while 68Ga-DOTATOC uptake did not (Malmberg et al., Journal of Nuclear Medicine, 2015, 56(12):1895-1900); the same biology means inflammation, thyroid disease, other receptor-expressing tumors and normal structures such as the uncinate process of the pancreas can take up the tracer without being a NET.

Research status

Copper Cu-64 dotatate reached the US market on a small evidence base from a Danish academic center and a single US sponsor.

First-in-humans (Copenhagen). Pfeifer et al. (Journal of Nuclear Medicine, 2012, 53(8):1207-1215) imaged 14 patients with known NETs with both 64Cu-DOTATATE PET/CT and the then-standard 111In-DTPA-octreotide SPECT/CT. PET identified additional lesions in 6 of 14 patients (43%), in 5 of them in organs not previously known to be involved, and every major PET-only finding was confirmed over 18 months of follow-up.

Head-to-head against indium-111 octreotide. The same group then prospectively enrolled 112 patients with confirmed gastroenteropancreatic or pulmonary NETs for paired 64Cu-DOTATATE PET/CT and 111In-DTPA-octreotide SPECT/CT within 60 days, with 42 to 60 months of follow-up (Pfeifer et al., Journal of Nuclear Medicine, 2015, 56(6):847-854). No SPECT-positive case was PET-negative, while PET found 10 SPECT false negatives. Sensitivity and accuracy were 97% for PET versus 87% and 88% for SPECT (p = 0.017), PET found twice as many lesions overall, and in 40 of 112 patients (36%) it showed disease in organs the SPECT scan had not. This dataset became Study 2 in the US label.

Head-to-head against gallium-68 DOTATOC. Johnbeck et al. (Journal of Nuclear Medicine, 2017, 58(3):451-457) scanned 59 NET patients with both 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT, with at least 30 months of follow-up for discordant lesions. The scans agreed on 701 lesions; 64Cu-DOTATATE showed 42 lesions not seen on 68Ga-DOTATOC, of which 33 proved true, while 68Ga-DOTATOC showed 26 unique lesions, of which 7 proved true, so 83% of the additional true lesions came from the copper tracer and additional true lesions were found in 13 versus 3 patients. Patient-level sensitivity was identical, since every patient with extra lesions also had concordant ones. The comparison was against DOTATOC, not DOTATATE, so it does not isolate the contribution of the radionuclide from that of the peptide.

The US pivotal trial. RadioMedix sponsored an open-label, single-center phase 3 study (NCT03673943) that ran from August 23, 2018 to a primary completion date of March 23, 2019 and enrolled 63 participants. Delpassand et al. (Journal of Nuclear Medicine, 2020, 61(6):890-896) reported it in two parts. A dose-ranging step in 12 patients identified 148 MBq (4 mCi) as the lowest activity giving diagnostic-quality images. Three nuclear medicine physicians masked to all clinical information then read scans from 42 NET patients and 21 healthy volunteers against a standard of truth set by an independent oncologist. The initial majority read gave 90.9% sensitivity (p = 0.0042) and 96.6% specificity (p < 0.0001); after correction of one standard-of-truth misread, sensitivity was 100% and specificity 96.8%. Reader reliability was high and no adverse events were attributed to the tracer. The label presents the same study by reader: agreement with the reference standard in disease-positive participants was 91% (95% CI 75% to 98%) for all three readers, and in disease-negative participants 97%, 80% and 90%, with the second reader calling 6 of 30 of them positive.

Routine use at scale. Rigshospitalet in Copenhagen adopted 64Cu-DOTATATE PET/CT for clinical routine on April 10, 2018, and Carlsen et al. (Journal of Nuclear Medicine, 2024, 65(11):1754-1761) reviewed every scan through May 2, 2022: 2,249 scans in 1,290 patients. Monitoring of known disease without clinical evidence of progression was the most common indication (703 scans, 31.3%), initial staging accounted for 221 (9.8%) and selection for or restaging after radioligand therapy for 95 and 115. Scans showed no disease in 29.7%, stable disease in 25.9% and progression in 20.5%, and in 99 of the 461 progression scans (21.5%) the progression was visible on PET but not CT.

Regulatory record. The FDA approved Detectnet (NDA 213227) on September 3, 2020 as a Type 1 new molecular entity with priority review and orphan drug designation. The approval letter records that the application was submitted on January 3, 2020 under section 505(b)(2) and that the orphan designation exempted the product from pediatric study requirements under the Pediatric Research Equity Act; the label states that safety and effectiveness have not been established in pediatric patients, unlike the gallium product, which carries a pediatric indication. One labeling supplement was approved on December 22, 2021, and the current prescribing information carries a January 2025 revision date. No marketing authorization for a copper Cu-64 dotatate product by the European Medicines Agency, Health Canada or other major regulators was identified as of November 2026; in Denmark the tracer has been in clinical routine use at Rigshospitalet since April 2018.

Active work. Registered studies as of November 2026 mostly explore the tracer outside its label, with the Copenhagen group probing the macrophage signal: an observational study in cardiac sarcoidosis in 76 participants (NCT06131112) and a 50-participant study in Lyme neuroborreliosis (NCT06392815), both listed as recruiting. Weill Cornell is running a 20-patient pilot of 64Cu-DOTATATE for intraoperative radio-guided meningioma surgery (NCT06377371, recruiting, estimated completion January 2027).

Common dosage forms

  • Detectnet. A ready-to-use sterile solution for intravenous injection, supplied as a 10 mL single-dose vial containing 148 MBq (4 mCi) of copper Cu 64 dotatate in 4 mL (37 MBq per mL) at calibration time, administered by licensed nuclear medicine personnel.
  • No kit or other presentation. There is no cold kit for on-site labeling; the drug is manufactured centrally and delivered as the finished radiopharmaceutical.

Key considerations

  • Regulatory status. The FDA Approved status reflects the September 3, 2020 approval of Detectnet (NDA 213227) for PET localization of somatostatin receptor-positive neuroendocrine tumors in adults. The approval was a 505(b)(2) application with priority review and orphan designation, the label covers adults only, and no approval outside the United States had been identified as of November 2026.
  • The advantage is logistical more than diagnostic. The 12.7-hour half-life permits central manufacture, overnight shipping and a 1-to-3-hour imaging window that gallium-68 cannot offer, but patient-level sensitivity equaled 68Ga-DOTATOC in the only published head-to-head PET comparison, which used DOTATOC rather than DOTATATE as the gallium comparator. In that study every patient with extra copper-tracer lesions already had concordant lesions on both scans.
  • A thin pivotal dataset. US approval rested on 42 NET patients and 21 healthy volunteers at one center, 88% of the patients already carrying a NET diagnosis, plus a retrospective analysis of the 112-patient Danish cohort. Agreement in disease-negative participants ranged from 80% to 97% across the three readers, and the label states that a negative scan in a patient without a NET history does not rule out disease.
  • Low positron yield and a mixed decay. Only 17.6% of copper-64 decays emit a positron, and the beta-minus and electron-capture branches contribute radiation dose without contributing signal; the labeled effective dose is about 4.7 mSv per scan, and the agent adds to cumulative radiation exposure. Hypersensitivity reactions, mostly rash and pruritus, are labeled from postmarketing experience with other somatostatin receptor imaging agents; in the trials themselves only nausea, vomiting and flushing occurred, each in under 2% of 71 participants.
  • Naming. Detectnet, 64Cu-DOTATATE, Cu-64 DOTATATE, copper Cu 64 dotatate and copper (64Cu) oxodotreotide all describe the same drug. Gallium Ga-68 dotatate (NETSPOT) and 68Ga-DOTATOC (edotreotide) are different approved imaging agents sharing the target, and lutetium Lu-177 dotatate is the therapeutic partner.